Feature | November 01, 2013

Trial Examines Benefits of iFR vs. FFR to Determine Severity of Coronary Artery Disease

Results of the ADVISE II Trial Presented at TCT 2013

cath lab clinical trial study fraction flow reserve FFR
November 1, 2013 — A study supports the use of instantaneous wave-free ratio (iFR) to simplify assessment and determine the severity of coronary artery disease (CAD). ADVISE II findings were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
ADVISE II enrolled 797 patients in a prospective, observational, non-randomized double blind global multi-center registry study with an adaptive design. The diagnostic performance of iFR was analyzed both as a dichotomous index and as part of a hybrid iFR/FFR strategy. iFR was used according to specific cutoffs (iFR zone, ? 0.85 and ? 0.94) with high positive and high negative predictive value for the detection of hemodynamically severe stenosis. FFR use was limited to the “adenosine zone” for iFR values between 0.86 and 0.93. The primary endpoint was the percentage of stenosis properly classified in terms of hemodynamic severity (FFR value ? 0.8). 
 
The final study population consisted of 690 stenoses and of these, 31 percent had an associated iFR value in the adenosine zone (0.86-0.93) while 69 percent had associated iFR values in the iFR zone. Within the iFR zone, the percentage of stenosis properly classified in terms of hemodynamic severity was 91.6 percent. Overall the hybrid iFR/FFR approach correctly classified 94.2 percent of coronary stenoses, without the need for adenosine administration in 65.1 percent of patients.
 
“The results of the ADVISE II study support the use of iFR to simplify physiological guidance of percutaneous coronary intervention,” said Javier Escaned, M.D, Ph.D., interventional cardiologist, Hospital Clinico San Carlos, Madrid, Spain, and lead investigator of the study.
 
“The promising results demonstrate the potential of boosting the benefits of ischemia-driven revascularization to a larger proportion of patients with coronary artery disease.”
 
For more information: www.crf.org

Related Content

Sci-image, Scimage, CVIS, CIIMS, Cpacs c-pacs, cardiovascular information system

Today's cardiovascular information systems need to incorporate all facets of the cardiology department, including subspecialties, to allow a complete picture of a patient's record. These data also need to be able to be shared with enterprise data systems, such as the electronic medical record (EMR). This image is from ScImage, illustrating the various aspects that integrate to make up a complete CVIS. 

 

Feature | September 29, 2016 | Val Kapitula, RT(R), PMP, CIIP
Cardiovascular Information and Imaging Systems (CVIS) have existed for many years in the dedicated sub-specialty area
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Avinger, U.S. Department of Veterans Affairs, VA, Lumivascular technology, FSS Contract Award
News | Optical Coherence Tomography (OCT)| September 27, 2016
Avinger Inc. recently announced the company has received an FSS Contract Award from the U.S. Department of Veterans...
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Overlay Init